SI-BONE 과거 순이익 실적
과거 기준 점검 0/6
SI-BONE은 연평균 18.8%의 비율로 수입이 증가해 온 반면, Medical Equipment 산업은 연평균 13.6%의 비율로 증가했습니다. 매출은 연평균 19.9%의 비율로 증가했습니다.
핵심 정보
18.77%
순이익 성장률
24.53%
주당순이익(EPS) 성장률
| Medical Equipment 산업 성장률 | 8.90% |
| 매출 성장률 | 19.87% |
| 자기자본이익률 | -9.33% |
| 순이익률 | -8.10% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
분석 기사 • May 14
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...
내러티브 업데이트 • Apr 12
SIBN: 2026 Guidance And Trauma Partnership Will Support Further Upside
Analysts have kept SI-BONE's price target steady at $22.00, citing only modest tweaks to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions, rather than any major change in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac joint fusion, expanding access to these products through Smith+Nephew's trauma portfolio and SI-BONE's existing sales channel (Key Developments).내러티브 업데이트 • Mar 29
SIBN: 2026 Outlook And Pelvic Fixation Partnership Will Support Upside
Analysts now hold their price target for SI-BONE steady at $22.00. This reflects only small tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially shift their overall valuation view.내러티브 업데이트 • Mar 11
SIBN: 2026 Revenue Outlook And Pelvic Fixation Deal Will Support Upside
Analysts have held their SI-BONE price target steady at $22.00, with only modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E, reflecting fine tuning rather than a shift in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac (SI) joint fusion, broadening access to these products through Smith+Nephew's trauma channel alongside SI-BONE's existing salesforce (Key Developments).내러티브 업데이트 • Feb 25
SIBN: 2026 Revenue Outlook And New Distribution Deal Will Support Upside
Analysts have trimmed their price target for SI-BONE from $23.00 to $22.00, reflecting updated assumptions that include slightly lower revenue growth expectations, a modestly higher profit margin outlook, and a revised forward P/E multiple. What's in the News SI-BONE issued earnings guidance for 2026, projecting worldwide revenue in a range of $228.5 million to $232.5 million, with implied year over year growth guidance of about 14% to 16% (company guidance).내러티브 업데이트 • Jan 19
SIBN: Higher 2025 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value estimate for SI-BONE at $23.00. They made small adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this reaffirmed target.내러티브 업데이트 • Jan 04
SIBN: Raised 2025 Revenue Guidance Will Drive Stronger Profitability And Share Price Upside
Analysts have modestly lowered their price target on SI-BONE to 23.00 dollars per share, reflecting a slightly higher discount rate and a marginally lower expected future price to earnings multiple, even as they factor in stronger long term revenue growth prospects. What's in the News SI-BONE raised its 2025 revenue guidance to a range of 198 million to 200 million dollars, up from 195 million to 198 million dollars previously.내러티브 업데이트 • Dec 19
SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside
Analysts have raised their price target on SI-BONE from 20 dollars to 23 dollars, citing slightly stronger expectations for revenue growth, profitability, and long term valuation multiples. What's in the News Company raised 2025 revenue guidance to a range of 198 million dollars to 200 million dollars, up from a prior range of 195 million dollars to 198 million dollars, signaling increased confidence in demand trends (company guidance filing) The updated outlook implies faster top line growth than previously anticipated and supports analysts' upward revisions to price targets and long term valuation assumptions (company guidance filing) The narrowing of the revenue guidance range suggests greater visibility into procedure volumes and commercial execution for the remainder of the year (company guidance filing) Valuation Changes The fair value estimate has risen slightly from 20 dollars to 23 dollars per share, reflecting modestly stronger growth and profitability assumptions.분석 기사 • Nov 13
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...분석 기사 • Nov 12
Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.1x may not look like an appealing investment...분석 기사 • Jun 26
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • May 09
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) investors will be delighted, with the company turning in some strong numbers with its...분석 기사 • May 08
Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders would be excited to see that the share price has had a great month, posting...분석 기사 • Mar 27
SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
새로운 내러티브 • Mar 26
TORQ And TNT Will Expand Market Reach In 2025
Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.분석 기사 • Jan 19
SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders have had their patience rewarded with a 26% share price jump in the last...분석 기사 • Nov 04
Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues
There wouldn't be many who think SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 3.7x is worth a...분석 기사 • Sep 25
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...분석 기사 • Apr 01
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.8x might make it look like a sell right now...분석 기사 • Feb 29
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
It's been a sad week for SI-BONE, Inc. ( NASDAQ:SIBN ), who've watched their investment drop 14% to US$17.35 in the...분석 기사 • Feb 28
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Nov 12
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Aug 09
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Apr 20
Is SI-BONE (NASDAQ:SIBN) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jan 01
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...매출 및 비용 세부 내역
매출 및 비용 세부 내역
SI-BONE가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 206 | -17 | 167 | 17 |
| 31 Dec 25 | 201 | -19 | 165 | 17 |
| 30 Sep 25 | 194 | -22 | 163 | 17 |
| 30 Jun 25 | 185 | -24 | 158 | 17 |
| 31 Mar 25 | 177 | -27 | 154 | 17 |
| 31 Dec 24 | 167 | -31 | 151 | 17 |
| 30 Sep 24 | 157 | -37 | 147 | 17 |
| 30 Jun 24 | 151 | -41 | 146 | 17 |
| 31 Mar 24 | 144 | -43 | 144 | 16 |
| 31 Dec 23 | 139 | -43 | 141 | 15 |
| 30 Sep 23 | 132 | -44 | 139 | 14 |
| 30 Jun 23 | 124 | -48 | 137 | 14 |
| 31 Mar 23 | 117 | -55 | 139 | 13 |
| 31 Dec 22 | 106 | -61 | 137 | 14 |
| 30 Sep 22 | 100 | -65 | 135 | 13 |
| 30 Jun 22 | 96 | -66 | 132 | 13 |
| 31 Mar 22 | 92 | -62 | 125 | 13 |
| 31 Dec 21 | 90 | -57 | 119 | 12 |
| 30 Sep 21 | 87 | -51 | 112 | 12 |
| 30 Jun 21 | 85 | -45 | 105 | 11 |
| 31 Mar 21 | 77 | -43 | 96 | 10 |
| 31 Dec 20 | 73 | -44 | 94 | 9 |
| 30 Sep 20 | 71 | -44 | 92 | 9 |
| 30 Jun 20 | 67 | -46 | 90 | 8 |
| 31 Mar 20 | 69 | -42 | 90 | 8 |
| 31 Dec 19 | 67 | -38 | 86 | 7 |
| 30 Sep 19 | 63 | -35 | 79 | 7 |
| 30 Jun 19 | 60 | -28 | 72 | 7 |
| 31 Mar 19 | 58 | -23 | 64 | 6 |
| 31 Dec 18 | 55 | -17 | 57 | 5 |
| 30 Sep 18 | 54 | -17 | 54 | 4 |
| 30 Jun 18 | 52 | -18 | 55 | 4 |
| 31 Mar 18 | 49 | -21 | 55 | 4 |
| 31 Dec 17 | 48 | -23 | 56 | 5 |
| 31 Mar 17 | 44 | -21 | 49 | 6 |
| 31 Dec 16 | 42 | -21 | 49 | 5 |
| 31 Mar 16 | 40 | -27 | 54 | 8 |
| 31 Dec 15 | 41 | -28 | 54 | 9 |
| 30 Sep 15 | 42 | -32 | 56 | 8 |
양질의 수익: SIBN 은(는) 현재 수익성이 없습니다.
이익 마진 증가: SIBN는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: SIBN는 수익성이 없지만 지난 5년 동안 연평균 18.8%의 속도로 손실을 줄였습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 SIBN의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: SIBN은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(14.8%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: SIBN는 현재 수익성이 없으므로 자본 수익률이 음수(-9.33%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 11:17 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
SI-BONE, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Travis Steed | BofA Global Research |
| Caitlin Cronin | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |